RDY

SEC filing RDY to Participate in Bank of America Investor Conference on June 5, 2026 in Hyderabad

1d ago

SEC filing RDY Files FY2026 Annual Report, $0 Revenue and EPS Not Disclosed, Financials Available on Company Website

1d ago

SEC filing RDY to Ring NYSE Closing Bell, Marks 25 Years Since First Asian Pharma Listing

5d ago

News Hims & Hers launches generics for Novo’s semaglutide in Canada

12d ago

News Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business

14d ago

News Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug

14d ago

News Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar

14d ago

SEC filing RDY Releases Q4FY26 Earnings Call Transcript, FY26 Results Available on Website

14d ago

SEC filing RDY Launches Generic Semaglutide Injection in Canada, First G7 Approval

17d ago

News Dr. Reddy’s to become first to sell Ozempic generics in Canada

20d ago

SEC filing RDY Reappoints Dr. K P Krishnan as Independent Director, Appoints Srikanth Velamakanni, Deloitte as Statutory Auditors

21d ago

SEC filing RDY Announces Health Canada Approval for Generic Semaglutide Injection in Canada, First Company to Receive Market Authorization, Launch Preparations Underway, GLP-1 Market Expansion, 3.9M Diabetics in Canada, 6% Prediabetes, In-House API Production, OneSource Manufacturing Partne

34d ago

SEC filing RDY Reports FY26 Results, $1.2B Revenue, $0.45 EPS, +18% YoY, Earnings Call May 12 10:00 AM ET

39d ago

SEC filing RDY Reports $1.2B Revenue, $0.45 EPS, +18% YoY, Awaits Health Canada Approval for Semaglutide, Received DINs April 22, 2026

39d ago

SEC filing RDY Reports $1.2B Revenue, $0.45 EPS, +18% YoY, Announces Final Dividend

47d ago

SEC filing RDY Reports $11.40M Penalty, RUB 9.27M RUS VAT Ruling, No Material Impact

48d ago

News Cheap semaglutide copies in India challenge Novo Nordisk, cut Eli Lilly’s lead: report

54d ago

SEC filing RDY Allots 3,675 Equity Shares at Re.1, Total Capital Rs.83,46,56,970, Lock‑in NA

68d ago

SEC filing RDY Amends Fair Disclosure Code, UPSI Rules, 24 March 2026

69d ago

SEC filing RDY Announces May 12 Board Meeting to Approve Audited FY2026 Results, Trading Window Closed Mar 25‑May 14

71d ago

SEC filing RDY Announces Launch of India’s First DCGI‑Approved Semaglutide Injection Obeda® for Type 2 Diabetes, Phase‑III Study Shows Non‑Inferior Efficacy, 2 mg/4 mg Pen Delivers 4 Doses, INR 4,200/Month Cost, Building GLP‑1 Portfolio Across Metabolic Disorders

71d ago

SEC filing RDY Receives GST Demand Orders FY20-22 Penalty 2.19B 50K 4K No Material Impact

76d ago

SEC filing RDY Immutep Halts TACTI-004 Phase III Efti Trial After Futility Review, Upfront Payment Made, Strategic Collaboration Continues

80d ago

SEC filing RDY Announces SEC Closes FCPA Probe, DOJ Closes Investigation, No Enforcement Action

88d ago

SEC filing RDY Receives USFDA Voluntary Action Indicated Closure of Srikakulam Facility, 2026 EIR Report

88d ago